Curanex Pharmaceuticals Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed by Curanex Pharmaceuticals Inc. (Nasdaq: CURX), a Nevada corporation, on January 5, 2026. The report covers events occurring on December 31, 2025, specifically regarding executive leadership changes.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The only financial figure disclosed is the annual compensation for the newly appointed Chief Financial Officer, set at $20,000 per year.
Material Changes
- Resignation: Haiyan Yang resigned as Chief Financial Officer and Treasurer effective immediately on December 31, 2025. The resignation was not due to any disagreement regarding the Company's operations, policies, or practices.
- Appointment: Wanjun Zhang was appointed as the new Chief Financial Officer and Treasurer, effective January 1, 2026.
- Compensation Agreement: A consulting agreement was executed on December 31, 2025, for an initial term of two years.
Outlook, Risks, and Management Commentary
Mr. Zhang brings over 20 years of financial experience, including prior roles as finance director for Perfect World (Beijing) Software Co., Ltd. (formerly Nasdaq-listed as "PWRD") and Beijing Huaxiahuitong Petty Loan Co. Ltd. His responsibilities will include accounting oversight, financial reporting, SEC filings, internal audit, and investor relations. The filing states there are no family relationships between Mr. Zhang and other directors or officers, and no undisclosed arrangements regarding his appointment.
Investor Verification Checklist
- Verify the effective date of the CFO transition (January 1, 2026) and the interim status of financial reporting.
- Review the attached Exhibit 10.1 (Consulting Agreement) for full terms beyond the summary provided.
- Confirm the Company's current cash position to ensure it can sustain operations and the new executive compensation without immediate capital raises.
- Monitor upcoming quarterly filings for any impact on financial controls or reporting timelines due to the leadership change.